The effects of pramipexole in REM sleep behavior disorder
- 25 November 2003
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Neurology
- Vol. 61 (10) , 1418-1420
- https://doi.org/10.1212/wnl.61.10.1418
Abstract
The authors evaluated the effects of pramipexole, a dopaminergic D2-D3 receptor agonist, on eight patients with idiopathic REM sleep behavior disorder. Five patients reported a sustained reduction in the frequency or intensity of sleep motor behaviors, which was confirmed by video recording, although no change was observed for the percentage of phasic EMG activity during REM sleep. Surprisingly, a decrease in the percentage of time spent with REM sleep muscle atonia was observed with treatment. The treatment did not modify the indexes of periodic leg movements.Keywords
This publication has 9 references indexed in Scilit:
- Periodic leg movements in REM sleep behavior disorder and related autonomic and EEG activationNeurology, 2002
- REM sleep behavior disorder and REM sleep without atonia in Parkinson’s diseaseNeurology, 2002
- Decreased striatal dopaminergic innervation in REM sleep behavior disorderNeurology, 2000
- Reduced striatal dopamine transporters in idiopathic rapid eye movement sleep behaviour disorderBrain, 2000
- Restless legs syndrome improved by pramipexoleNeurology, 1999
- Rapid eye movement sleep behavior disorder preceding Parkinson's disease with therapeutic response to levodopaMovement Disorders, 1996
- Delayed emergence of a parkinsonian disorder in 38% of 29 older men initially diagnosed with idiopathic rapid eye movement sleep behavior disorderNeurology, 1996
- Polysomnographic features of REM sleep behavior disorderNeurology, 1992
- REM Sleep Behavioral DisordersEuropean Neurology, 1988